NC410, a bivalent LAIR-2 construct, remodels collagen in the tumor microenvironment and abrogates neutrophil-driven T cell suppression

Thejaswini Giridharan & Brahm H Segal et al.

Abstract

We previously observed that circulating human neutrophils exposed to epithelial ovarian cancer (OC) ascites fluid supernatants (ASC) and malignant effusions from other tumors acquire T cell suppressor function. Collagen motifs ligate LAIR-1, an inhibitory SHP-1-dependent checkpoint broadly expressed on immune cells. We hypothesized that NC410, a bivalent LAIR-2 construct that inhibits LAIR-1-collagen binding, would rescue neutrophil-driven T cell non-responsiveness. NC410 remodeled ASC collagen resulting in neutrophil clustering and reduction in neutrophil-T cell contact, abrogated ASC-induced neutrophil trogocytosis of T cell membranes and rescued stimulated T cell proliferation. Mean ASC pro-collagen-1α levels were >100-fold greater than serum samples. In a single-center retrospective analysis, after adjusting for age, stage and optimal debulking, ASC pro-collagen-1α and serum sLAIR-1 levels were each associated with worse overall survival (OS), and ASC LAIR-2 levels were associated with better OS. Multispectral imaging of high-grade serous ovarian cancer and non-small cell lung cancer showed highly variable LAIR-1 staining in both tumor cell and immune infiltrates. The proportion of collagen-1-positive cells was highest among tumor cells and tumor-infiltrating immune cells versus stromal immune cells, raising the potential role of tumor-associated collagen limiting immune cell infiltration into tumor. Our results support further evaluation of circulating and tumor-associated collagen products and LAIR-1 and LAIR-2 as prognostic biomarkers in advanced OC and as biomarkers for clinical response to NC410 and to other collagen- and LAIR-directed therapies.

Authors
Thejaswini Giridharan, Sora Suzuki, Anm Nazmul H Khan, Qian Liu, Kristopher Attwood, Anna Stokolosa, Sidney Mahan, Agnieszka K Witkiewicz, Janine Joseph, Kirsten Moysich, Solomon Langermann, Rustin Lovewell, Dallas Flies, Han Myint, Kunle Odunsi, Tiffany R Emmons, Michael B Yaffe, Emese Zsiros, Prasenjit Dey, A J Robert McGray, Brahm H Segal
Funding

BHS

NCI NIH HHS

R01CA267690

KBM

R01CA267690

NextCure Inc.

NCI NIH HHS

R01 CA267690

Comprehensive Cancer Support

NCI Comprehensive Cancer Support Grant

NCI NIH HHS

P30 CA016056

NCI NIH HHS

R01CA188900

NextCure Inc

NCI NIH HHS

R01 CA188900

Roswell Park Comprehensive Cancer Center

5P30CA016056

NCI

R01CA188900

NCI

R01CA267690